Stephen Jackson and Samah Awwad receive an ASPIRE II award

The Mark Foundation for Cancer Research announced 16 outstanding projects in its latest class of ASPIRE awards granting more than $5 million for research that aims to answer key feasibility and proof-of-concept questions in an accelerated time frame, and scaling for impact based upon initial success. The high-risk nature of these projects, often based on new ideas that have generated limited preliminary data, tends to place them outside the scope of other funding opportunities.

Steve Jackson and postdoc Samah Awwad are recipients of an ASPIRE II award “Dissecting molecular mechanism(s) of ATR-inhibitor and CHK1-inhibitor sensitivity and resistance”. Further information about this project and the other ground-breaking research funded by the Mark Foundation for Cancer Research can be found here.